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On-chip preparation of nanoscale contrast agents
towards high-resolution ultrasound imaging†
Sally A. Peyman,a James R. McLaughlan,b Radwa H. Abou-Saleh,ad
Gemma Marston,c Benjamin R. G. Johnson,a Steven Freear,b P. Louise Coletta,c
Alexander F. Markhamc and Stephen D. Evans*a
Micron-sized lipid-stabilised bubbles of heavy gas have been utilised as contrast agents for diagnostic ultra-
sound (US) imaging for many years. Typically bubbles between 1 and 8 μm in diameter are produced to en-
hance imaging in US by scattering sound waves more efficiently than surrounding tissue. A potential area
of interest for Contrast Enhanced Ultrasound (CEUS) are bubbles with diameters <1 μm or ‘nanobubbles.’
As bubble diameter decreases, ultrasonic resonant frequency increases, which could lead to an improve-
ment in resolution for high-frequency imaging applications when using nanobubbles. In addition, current
US contrast agents are limited by their size to the vasculature in vivo. However, molecular-targeted nano-
bubbles could penetrate into the extra-vascular space of cancerous tissue providing contrast in regions in-
accessible to traditional microbubbles. This paper reports a new microfluidic method for the generation of
sub-micron sized lipid stabilised particles containing perfluorocarbon (PFC). The nanoparticles are pro-
duced in a unique atomisation-like flow regime at high production rates, in excess of 106 particles per s
and at high concentration, typically >1011 particles per mL. The average particle diameter appears to be
around 100–200 nm. These particles, suspected of being a mix of liquid and gaseous C4F10 due to Laplace
pressure, then phase convert into nanometer sized bubbles on the application of US. In vitro ultrasound
characterisation from these nanoparticle populations showed strong backscattering compared to aqueous
filled liposomes of a similar size. The nanoparticles were stable upon injection and gave excellent contrast
enhancement when used for in vivo imaging, compared to microbubbles with an equivalent shell
composition.
Introduction
Microbubbles (MBs) have been widely employed as ultra-
sound (US) contrast agents in medical imaging.1 They typi-
cally contain a heavy gas core, such as a perfluorocarbon
(PFC) gas, and a lipid,2 protein, or polymer shell and are
between 1 and 8 μm in diameter (Fig. 1).3 Microbubbles pro-
vide contrast in US imaging by scattering ultrasound waves
more efficiently than the surrounding tissue and recently
there has been much interest in developing molecular-
targeted microbubbles4 and in using them as devices to
enhance therapeutic delivery and uptake.5,6 When the drug to
be delivered is physically attached to the MB they are known
as theranostic agents.7
An emerging area of interest is that of sub-micron
bubbles. Nanobubbles, also defined as ‘ultra-fine bubbles
(50 nm–1 μm) have been the subject of much interest
recently due to their potential for widespread commercial
application in a diverse range of fields; from ‘eco-cleaning’
for removing dirt, salt, etc. from surfaces without the use of
surfactants,5 in the microfabrication industry for the floata-
tion separation of semiconductor water treatment through to
agriculture and plant irrigation.8–10 The nanobubbles are gen-
erally formed via a gas nozzle submerged in water creating a
high velocity jet6–8 and are purported to be stable for
prolonged periods, from weeks up to several months, even in
the absence of surfactant coatings.10,11 As the Laplace
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S1: video of a bubble sample in a viewing chamber showing microbubbles rising
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pressure is inversely proportional to the diameter of a bubble
one would expect that the pressure inside the bubbles would
be too great for them to exist for longer than a few microsec-
onds.12 There have been some conflicting theories as to the
origin of the stability of such nanometer sized bubbles of gas
in water ranging from; a lack of buoyancy, and an associated
reduction in coalesce with the liquid–air interface at the top
of a vial8 to changes in the structure of the water at the nano-
bubble–gas interface. Ohgaki et al., used ATR-IR to study the
water–air interface and suggested that ‘hard’ hydrogen bonds
similar to those found in ice promoted nanobubble longevity
by containing the high internal pressures of the nanobubble
and limit the diffusivity of gas out of the bubble and into the
surrounding solution.11
Several groups have investigated the applicability of nano-
bubbles for Contrast Enhanced Ultrasound (CEUS). Xing
et al. found that 400–600 nm diameter nanobubbles,
produced by sonication, provided enhancement in in vivo US
imaging.13 Further, nanobubbles produced by mechanical
agitation methods have been reported to display superior
performance characteristics in vivo when compared to
commercially available microbubbles in terms of contrast
intensity and longevity.14,15 The use of nanobubbles as drug
delivery vehicles has also been investigated.16 Zhang et al.
who reported that nanobubbles formed by sonication, could
be used as drug carriers for the treatment of residual tumour
cells during High Frequency Ultrasound (HIFU) ablation.
Nanobubbles loaded with methotrexate were described as a
synergistic therapy, delivering the anti-cancer drug during
the HIFU therapy to improve overall efficiency of tumour
ablation.17 Cavalli et al. demonstrated nanobubbles formed
using an homogeniser as carrier agents for US mediated gene
delivery.18
Nanobubbles have potential advantages over their micron-
sized counterparts due to their ability to perfuse into
tumours, through ‘nanopores’ in found in tumour blood
vessels. These pores are of the order of 380–780 nm in diame-
ter depending on the type of tumour.14,19 This uptake of
nanometer sized material, known as the enhanced permeabil-
ity and retention or the EPR effect, could also improve drug
delivery using nanobubbles by allowing deeper penetration
of the delivery vehicle into the tumour. The Lapotko group
have investigated another interesting potential application of
nanobubbles in the clinic – the plasmonic nanobubble.
Nanobubbles are generated by heating gold nanoparticles
with a laser pulse. The group demonstrated that nanobubbles
of controlled size could be produced by tuning the energy of
laser and used for detection of cancerous cells or the selective
destruction of the cell with mechanical ablation.20 In a differ-
ent example the nanoparticle–nanobubble technology was
used for drug delivery by encapsulating nanoparticles and
drugs inside a liposome. Nanoparticles were then overheated,
producing nanobubbles which caused disruption of the lipo-
some membrane and ejection of the drug payload.21
The preparation method of nanobubbles varies depending
on the application. Industrial scale nanobubble preparation
involves large volumes and high energy requirements, which
has been suggested will limit their widespread us.8 In his
review, Zimmerman concluded that if energy efficient nano-
bubbles could be made, there would be widespread uptake of
the technology.8 Nanobubble fabrication techniques for med-
ical applications have employed either sonication or mechan-
ical agitation methods coupled with several labour intensive
steps to attach drug or gene payloads to the nanobubble,
depending on the biochemical complexity of the bubble
shell.15–17,22 Repeat handling of bubble samples can cause
bubble loss through dilution or destruction and lower final
bubble numbers.
Another, alternative method for producing microbubbles
is the phase conversion of nano- or micro- meter sized low-
boiling point PFC liquid droplets into PFC bubbles. The pro-
cess, termed acoustic droplet vaporisation, is driven by pres-
sures associated with an ultrasound wave.23 Similarly an
increase in temperature can also activate the droplets into
bubbles by causing thermal expansion of the low-boiling
point liquid. Phase-change contrast agents have shown excel-
lent echogenicity during in vitro24,25 and in vivo studies.26
The nano- and micro- droplets generated for these applica-
tions are produced either by extrusion27 or microbubble con-
densation, in which microbubbles are formed initially before
being pressurised and slow-cooled to a liquid.24
A relatively new technology for the production of micro-
bubbles is the use of microfluidics. There has been much
work in recent years on the production of monodisperse
micron sized bubbles for CEUS applications. Flow focussing
microfluidic designs allows for greater control over the size
of microbubbles produced and their polydispersity.28–30 For
example, Hettiarachchi and Talu et al. produced 1–5 μm
microbubbles with a dispersity index of <5%.31,32 A similar
approach for making uniformly sized phase-change contrast
agents was described in which monodisperse microbubbles
Fig. 1 Lipid stabilised nanoparticles in aqueous solution showing lipid
monolayer shell. The C4F10 may exist as a liquid core or a gas core
depending on the size of the nanoparticle (r) and the surface tension
(σ) (not to scale).
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where produced on-chip prior to bubble condensing into
droplets.33
However, despite the elegant control over microbubble
size, the above approaches suffer from low microbubble con-
centrations, which greatly limit their clinical applicability.
We recently demonstrated that by introducing a sudden pres-
sure drop, through expansion in outlet geometry of the chip
that microbubbles could be produced in a ‘microspray’ re-
gime, generating microbubbles at concentrations >109
microbubbles per mL, a vast improvement on other micro-
fluidic approaches. The microchip–microspray approach is
simple to operate, highly reproducible and cheap to manufac-
ture. The same design was also demonstrated for the rapid,
single-step functionalisation of microbubbles with a thera-
peutic payload for targeted drug delivery.2,34
In this paper, we show that this same microchip and
microspray regime leads to the facile production of high con-
centrations of nano-sized lipid stabilised PFC particles,
~1011–1012 mL−1, which dependent on their composition, size
and surface tension exist in either their gaseous or liquid
phase. For simplicity the mixed populations of nanobubbles
and nanodroplets shall be referred to collectively as PFC
‘nanoparticles.’ Both nanodroplets and nanobubbles are
thought to be acoustically active. Nanodroplets can undergo
phase change into nanobubbles on application of tempera-
ture rise or a negative pressure US field.23 In experiments
where nanoparticles are exposed to ultrasound, they will be
referred to as ‘nanobubbles.’ To our knowledge this is the
first example of microfluidic production of high concentra-
tions of nanoparticle phase change agents. The size and con-
centration of the nanoparticles produced by the microspray
regime was characterised using a combination of comple-
mentary measurement techniques based on particle counting
using a miniaturised coulter counter, dynamic light scatter-
ing (DLS) and particle tracking analysis. The response of the
nanoparticles in an US field was also investigated both in a
phantom, using a 15 MHz transducer, and in in vivo models,
with a 40 MHz transducer. The nanoparticles showed supe-
rior contrast intensity in vivo when compared to the micro-
bubbles samples, demonstrating their suitability as efficient
contrast agents. Nanoparticles of PFC show the potential to
improve spatial resolution for imaging using high frequency
transducers (25–80 MHz), as used in pre-clinical imaging or
in high frequency clinical US imaging applications.35,36
Experimental
Materials
Microbubbles and PFC nanoparticles were prepared from
C4F10 gas purchased from Air Liquide (Birmingham, UK), the
surface coatings consisted of a lipid mixture (23.5 μL DPPC
at 20 mg mL−1 and 3.5 μL DSPE-PEG2000 at 25 mg mL−1)
purchased from Avanti Polar Lipids (Alabaster, Al, USA).
All lipids were dissolved in chloroform, dried on the wall of
a glass vial under nitrogen for 40 minutes and then re-
suspended in phosphate buffered saline (PBS, Sigma-Aldrich,
UK). The vial was then vortexed for 1 minute and placed
in a heated ultrasonic bath for 1 hour to facilitate the re-
suspension of the lipid mix.
Microfluidic design and bubble generation
The microfluidic devices were fabricated by Epigem Ltd
(Redcar, UK) in PMMA (polymethylmethacrylate) and SU-8.
The microfluidic design had been described previously34 but
briefly, it consists of a central inlet channel for the gas and
two opposing inlet channels for the introduction of the liquid
phase. The flow was focussed through a nozzle beyond which
there was a single exit channel. The chips were fabricated to
a depth of 25 μm, apart from the exit channel which had an
additional 25 μm depth, giving an overall depth of 50 μm.
The expanding 3D geometry was multiplexed to provide four
bubble making geometries per chip to speed production. The
chips were mounted in a custom-built holder on the move-
able stage of an inverted light microscope (Eclipse Ti-U,
Nikon, Japan). The chip holder consisted of a recess into
which the microchip fitted closely. A manifold, which
contained PTFE tubes (Supelco Analytical, USA) for liquid
and gas lines was brought into firm contact with the chip
using a lever clamping arm. In the closed position a gas tight
seal between the manifold and chip was formed, even under
high pressure conditions (>40 psi). Fluid flow to the micro-
chip was delivered via a Mitos P-Pump (Dolomite Ltd, UK)
and the gas was regulated by a digital gas flow controller
(Alicat Scientific, USA).
Microbubbles and nanoparticles were generated by
pumping the aqueous lipid solution through opposing inlets
and a gas flow through the central inlet (Fig. 2a). Liquid flow
rate was 90 μL mL−1 and gas pressure set at 15 psi. A small
delay, of a few seconds, was implemented before starting the
bubble collection to ensure flow rates and gas pressures had
reached their desired rate.
Bubble separation and sizing
Microbubbles were separated from nanoparticles over time
by a passive method that relies on the intrinsic buoyancy of
the bubbles. A spherical bubble in a liquid medium has an
ascension velocity, U, which can be calculated from the
Hadamard–Rybczynski eqn (1).37
(1)
Where R is the radius, g is the gravitational acceleration
(9.8 m s−1), μ is the dynamic viscosity of water (8.90 × 10−4 Pa s),
μ′ is the dynamic viscosity of C4F10 (1.2 × 10
−5 Pa s) and Δρ is
the difference in density between the medium and the gas
core.37 For a bubble with a 2 μm diameter it would take
23 minutes to rise a distance of 1 cm. For a bubble with a
diameter of 150 nm it would take 17 hours to travel the same
distance. In the case of a nanodroplet with a diameter of
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150 nm, and a density of 1594 kg m−3 it would sink by
1.2 μm over the same time (23 min), and can be thought of
as neutrally buoyant for these experiments. Based on this the
bubble sample was left for ~45 minutes to allow bubbles
larger than 1 μm to rise to the top of the vial, leaving behind
the nanobubbles and neutrally buoyant nanodroplets. Nano-
bubbles and droplets do not scatter light as much as micro-
bubbles and do not appear turbid to the eye. After 45
minutes the top layer of microbubbles was removed with a
pipette and samples were taken from the lower, clear, portion
of the vial. Sizing and counting of the separated samples was
performed on a qNano (Izon, UK), via DLS (Zetasizer,
Malvern Instruments, UK) and by a NanoSight instrument
(Malvern Instruments, UK). For qNano measurements pore
sizes of 100 nm up to 4000 nm were used to investigate the
nanoparticle/bubble size ranges within the samples. Samples
were diluted 1 in 100 prior to measurements. Microbubble
samples were counted optically according to the methods
published previously.34
Ultrasound characterisation
Acoustic backscatter from bubble populations was measured
using a focused 15 MHz single element ultrasound trans-
ducer (V313, Olympus KeyMed Ltd, Essex, UK) situated in a
tank of degassed and filtered water. The ultrasound trans-
ducer was connected to a pulser/receiver (5072PR, Olympus
KeyMed Ltd, Essex, UK), which generated a broadband ultra-
sound pulse that was scattered by the nanobubble/liposome
populations. The populations were contained within a 100
mL cylindrical chamber that had acoustic windows to allow
for interrogation of ultrasound, and were magnetically stirred
to ensure a uniform distribution of particles. The
backscattered signals were filtered (1 MHz high pass) and
amplified by a 20 dB pre-amplifier built into the pulser/re-
ceiver unit. The filtered and amplified signal was digitised at
a sampling frequency of 5 GHz using an 8 bit oscilloscope
(LeCroy 64Xi, LeCroy Corporation, Chestnut Ridge, NY) and
downloaded to a PC. A total of 500 pulses were recorded at a
pulse repetition frequency (PRF) of 0.5 kHz for each particle
population, which were processed using Matlab (MathWorks
Inc., Natick, MA). The received signal spectra were averaged
in the frequency domain to reduce the variance of the experi-
mental results due to external noise sources.38 This process
was repeated (n = 3) for each population tested.
In vivo imaging
Three CD1 nu/nu male mice age 6–8 weeks were imaged at
40 MHz with the VisualSonics Vevo770 High Frequency Ultra-
sound (HFUS). Mice were initially anaesthetised with 5% v/v
isofluorane in medical air, which was then maintained at 3%
during the imaging procedures. The aorta of the mouse was
identified by an experienced HFUS user, with arterial flow
confirmed with Pulsed Waved (PW) Doppler imaging. A 50
μL bolus of ~1 × 109 microbubbles per mL or 1012 nanoparti-
cle per mL sample (maximum gas volume fractions of 4.2 ×
10−9 m3 and 1.8 × 10−9 m3, respectively) was administered via
a tail vein catheter at a rate of 0.6 mL min−1, controlled via a
syringe driver. Imaging was carried out under contrast
B-mode, to acquire bubble wash-in curves for quantitative
analysis with the wash in of bubbles. Data was analysed post
acquisition with VisualSonics software to analyse time inten-
sity wash-in curves and determination of Imin, Imax, and flow
rate.
Both in vitro and in vivo ultrasound systems were
characterised using a calibrated 40 μm needle hydrophone
(Precision Acoustics, Dorchester, UK). The in vitro system
generated a 3-cycle pulse that had a peak positive pressure of
3.90 ± 0.08 MPa, and a peak negative pressure of 2.98 ± 0.04
MPa, which corresponded to a mechanical index (MI) of
0.74.39,40 An A-line generated by the in vivo system consisted
of a 2-cycle pulse, that in the focal region, had a free field
peak positive pressure of 2.6 ± 0.15 MPa, and a free field peak
Fig. 2 (a) Microspray bubble formation in a flow focussing microfluidic device featuring a 3D expanding geometry. (b) Histogram of bubble sizes
when counted optically. Green shaded area indicates the optical limit (~0.75 μm) where nanoparticles are not resolved and counted. Insert shows
a typical optical image of the microbubbles.
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negative pressure of 2.89 ± 0.02 MPa, which corresponded to
an MI of 0.49.
Results and discussion
Nanoparticle generation
Fig. 2a shows the microspray bubble formation regime gener-
ated in the 3D expanding geometry chips. The C4F10 gas at a
pressure of 15 psi (1.034 × 105 Pa) in the central channel is
focused through the nozzle from inlet channels either side by
a 0.5 mg mL−1 aqueous solution of lipids, typically at a flow
rate of 90 μL min−1. As the gas and lipid solutions are
pumped through the nozzle they experienced very high shear
forces and velocity gradients. Immediately following the
nozzle the 3D-expansion in the outlet caused a pressure drop
in the outlet, inducing atomisation-like break-up of the gas
cone and releasing bubbles in a fine spray. This atomisation-
like behaviour produces a high concentration of microbubbles
in the 108–109 bubbles per mL with a size range between 1
and 8 μm, when counted optically (×60 optical magnification).
The histograms of microbubble diameter, Fig. 2b, appear
asymmetric; with a cut off for lower bubble size ~0.75 μm
(the insert shows a brightfield image of the microbubbles).
The lowest size on the histogram corresponds to the limit of
the optical resolution of the 60× magnification used to count
bubbles. In addition, optical images were taken at the upper
surface of a flow cell, in which the bubbles have risen due to
their intrinsic buoyancy. However, nano-sized particles such
as nanodroplets and even nanobubbles, that are much
smaller in size, remain homogenous in suspension due to
Brownian motion. When the focus of the microscope was
adjusted to go through a whole depth of the bubble sample,
very tiny particles were observed moving with Brownian
motion beneath the microbubble layer on top (see ESI† S1)
suggesting there was a population of sub-micron particles
produced during this regime that cannot be counted
optically.
Fig. 2a shows an optical image taken of the microspray
production at 90× magnification and the gas cone appears to
show micron-sized bubbles breaking off the interface with
the lipid solution. However, a finer spray of smaller particles
can also be observed as a darker region very near to the
nozzle.
Several papers have been published on the fluid mechan-
ics behind high-pressure gas jets in liquid and the break up
mechanisms that give rise to bubble production. Chen and
Richter describe the process of bubbling and jetting in re-
gimes under high gas pressures and turbulent flow.41 The
distinction between the two regimes depends on the linear
velocity of the gas flow. Instances when the gas jet is sub-
sonic (less that Mach 1) the gas cone breaks up into bubbles.
When the velocity is supersonic (larger than Mach 0.9) then
the gas cone moves into the jetting regime and breaks up
some distance from the nozzle. In the case of the microspray
regime, the linear velocity of the fluid can be easily calculated
in the nozzle and equates to 5 m s−1. This would give the
liquid alone a value of Mach 0.3. The Reynolds number in-
side the nozzle was calculated to be ~82, much higher than
usually expected in microfluidic devices. However, this does
not take into account the velocity of the gas jet, which cannot
be measured using the current set-up. It may be that the lin-
ear velocity is even higher, pushing the Mach number up to
unity.
A high-speed camera (SIMX16, Specialised Imaging, UK)
was used to try to observe this phenomenon at a frame rate
of ~1 billion fps. However, the microspray break up was still
too fast to observe individual bubbles and droplets (ESI† S2).
Again, this suggested that the velocities in the channel were
extremely high, potentially in the super-sonic range.
Nanoparticle sizing and stability
Suspensions of PFC nanoparticles generated in the micro-
fluidic device as described above were measured using a com-
bination of methods. For bubbles of diameter 1 μm and up-
wards optical counting (Fig. 2b) and electrical conductance
(qNano) methods showed good agreement in estimating both
bubble size and concentrations. Concentrations were typically
of the order of 108 bubbles per mL. The region of the histo-
gram, in Fig. 2b, defined by the green box corresponds to the
range of nanoparticles sizes whose diameter was below the
resolution capabilities of the optical microscope. In this re-
gime the particle size/concentration was determined both
electrically using the qNano or via particle tracking using the
NanoSight. The NanoSight data in Fig. 3 indicates a high
concentration of particles ~1010 mL−1 for particles of diame-
ter in the range 100–300 nm (the qNano data indicated parti-
cle concentrations up to 1012 particles per mL).
Fig. 3 Particle size of nanoparticles of C4F10 as determined by particle
tracking. Inset: TEM image of nanoparticles of C4F10.
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Fig. 4a shows the phase change behavior measured using
the Zetasizer as a function of temperature. Particle size was
measured in ~10 °C steps, for temperatures below 45 °C the
nanoparticles were in a liquid state and the size profile did
not alter as a function of temperature. The solid circles in
Fig. 4a is the average distribution profile for all data obtained
below 45 °C. On heating above 57 °C the droplets phase-
changed in to a gaseous state (solid squares). Fig. 4b shows
the dependence of phase-change temperature for C4F10 as a
function of droplet diameter for different surface tensions.
The phase change temperature observed in our system (i.e.
<60 °C) would therefore suggest that the surface tension of
our droplets is low and probably between 10 and 15 mN m−1.
The difference in size observed between data from the Nano-
Sight (Fig. 3) and initial size measurements on the DLS
(Fig. 4a) are likely to be due to changes in the sample over
time. The same sample was used for both measurements, but
the DLS was run two hours after the NanoSight in which the
sample was left standing at room temperature. It is likely that
some of the larger gas filled particles picked up by the Nano-
Sight have shrunk and condensed to liquid phase C4F10 be-
fore being run on the DLS. In addition, some of the larger
bubbles will have risen from the bottom of the tube where
the sample was taken from. The sample was not agitated in
this time to avoid any microbubbles that had risen to the top
being mixed back into the sample.
Such low surface tensions would lead to droplets larger
than 315 nm being in the gaseous phase whilst smaller ones
would remain as liquid droplets. Based on an estimated sur-
face tension of 10 mN m−1 we can calculate the predicted dis-
tribution of bubble sizes, from the initial droplet size distri-
bution, the hollow squares in Fig. 4a was calculated based on
the model developed to estimate the “Expansion Ratio” using
the approach of Evans et al.42 The “Expansion Ratio” data are
provided in the supplementary material (ESI† S4).
A control lipid solution, of the same lipid concentration as
used for bubble formation that had been pumped through
the tubing, but not the microfluidic device was analysed on
the NanoSight. Vesicles in the lipid solution had a much
broader size range and lower concentration as particle than
after nanobubble/droplet formation in the fluidic device
(ESI† S5).
The time dependent behaviour of the particles in terms of
size and concentration were also investigated on the qNano.
Samples of subnatant collected after separation were kept in
the fridge (4 °C) for a period of 17 days and measured on the
qNano at different time intervals. Fig. 5 shows the average
particle diameter (red axis) and particle concentration (black
axis) over time. The data shows that the particles remained
stable over the 17 day period with little change in particle
diameter or concentration, remaining at ~260 nm in diame-
ter and 4 × 1011 particles per mL, respectively. The particles
were only measured on the 200 nm pore as this covered the
greatest range of particle sizes within the range of interest
compared to other pores (100–400 nm).
Ultrasound measurements
Due to the acoustic impedance mismatch between bubbles
and the surrounding liquid we would expect to distinguish
between sub-micron sized bubbles and particles, such as
liposomes, by measuring the US backscatter from the samples.
We would also expect any small particles containing a liquid
Fig. 4 Nanodroplets undergoing thermally induced phase change to
gas bubbles. (a) Shows the initial droplet size-distribution (solid red
circles), the predicted profile following phase conversion (hollow red
circles) and the experimentally determined bubble size post phase
conversion (solid blue squares). (b) Shows the calculated phase change
temperature, for C4F10, as a function of droplet size for different drop-
let surface tensions.
Fig. 5 Stability testing of nanoparticles measured on the 200 nm pore
on the qNano. Nanoparticles kept in the fridge at 4 °C showed
excellent size (red) and concentration (black) stability over a 17 day
period.
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C4F10 core to phase change during exposure to the ultrasound
field.23 Suspensions of bubbles and nanoparticles were gener-
ated in the microfluidic device as described above. Fig. 6A
shows the backscattered US signal from solutions of filtered
water containing a concentration of 2 × 106 particles per mL of
either liposomes or nanoparticles. The scattering signal was
corrected for the response of the 15 MHz ultrasound trans-
ducer used for this study. In addition, only data acquired
within the measured 6 dB bandwidth of the transducer is
displayed. The PFC filled nanoparticles showed between a 15–
20 dB increase in backscattered signal over equivalent size and
concentration of water filled liposomes.
Calculation of the ultrasound response as a function of
bubble size (after phase change) predicts that as bubble di-
ameter decreases below 1 μm, the resonant frequency of the
bubble increases dramatically >15 MHz (ESI† S6). Fig. 6B
shows the expected resonant frequency response of the nano-
bubbles used in these experiments, based on their size distri-
bution. Shell parameters for the commonly used phospho-
lipid ultrasound contrast agents, SonoVue and Definity were
used for this calculation. This indicates that the nanobubble
populations generated in this study would have a theoretical
peak resonant frequency at ~60 MHz, but with a range be-
tween 15 to >100 MHz which is supportive of the observa-
tions made in the backscatter measurements shown in
Fig. 6A, where the backscatter of the nanobubbles increases
at higher frequencies. This also suggests that the nano-
bubbles would give even greater backscatter at frequencies
higher than the transducer used in these experiments. Many
pre-clinical US imaging systems use high frequency trans-
ducers in the range 40 to 80 MHz (ref. 43–46) with recent ad-
vances to 100 MHz,47,48 which may be indicative that the
nanobubbles will show enhanced contrast and be useful as
higher resolution image contrast agents for preclinical imag-
ing and high frequency clinical imaging.
In vivo characterisation
The in vivo behaviour of the nanoparticle samples was inves-
tigated in mouse aorta models using the VisualSonics Vevo
770 pre-clinical imaging system with a 40 MHz transducer.
Three CD1 nude mice were imaged using HFUS as de-
scribed above, each with a different preparation of bubbles
or particles; either a raw population of microfluidic bubbles
(containing both microbubbles and nanoparticles), or micro-
bubbles or nanoparticles isolated by buoyancy separation.
The HFUS images were false coloured (in green) in order to
display the change in contrast when the bubble populations
were introduced into the vascular system (Fig. 7). A basic
comparison between the maximum contrast intensity
achieved with each bubble preparation, was done, with the
peak intensity from the wash-in curve determined. The peak
intensity from the mixed bubble/particle population
(Fig. 7(a)) and the nanoparticles population (Fig. 7(b)) were
very similar (288 and 296 arbitrary units (A.U.), respectively),
and both were much greater than the microbubble only
population (Fig. 7(c)) (97 A.U.). These data suggest that the
majority of signal seen (with the VisualSonics Vevo 770
40 MHz system) in the mixed bubble/particle population is
attributable to the nanoparticle component, with a much
lower proportion of the signal coming from microbubbles.
Time vs. intensity curves (TIC) for the different samples were
also taken, the microbubble only sample (from the separated
mix) and nanoparticle only sample (from the separated mix)
has been added to the ESI† (S7). From the TIC curves, the
longevity of the nanoparticle sample compared to the micro-
bubble only sample can clearly be seen, with contrast inten-
sity at >131 lasting 40 s post injection. This was also compa-
rable to the whole mixed population of microbubbles and
nanoparticles, which showed a contrast intensity of over 100
for the 40 s post injection, suggesting at these higher fre-
quencies much of the contrast signal observed was from the
Fig. 6 (a) Ultrasound backscatter signal of nanoparticles and
liposomes. Over the 6 dB bandwidth of the ultrasound transducer the
nanobubbles showed between a 15–20 dB increase in signal over an
equivalent size and concentration of liposomes. A 15 MHz transducer
was used in conjunction with a pulser/receiver to transmit a
broadband ultrasound signal and detect the backscatter. Error bars
represent the standard deviation of the measured backscatter for three
repeat samples. (b) Distribution of calculated resonance frequencies
for a population of nanobubbles – showing a peak resonant frequency
of ~55 MHz. The plot shows the US frequency ranges for both clinical
and pre-clinical imaging.
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nanoparticle fraction. The high contrast intensity observed
from mixed bubble and nanoparticle only samples in in vivo
experiments could be attributed to two factors. The first
being that a higher frequency transducer (40 MHz) was used
for these experiments, which is much closer to the expected
resonant frequency of the sub-micron bubbles (60 MHz) than
the 15 MHz transducer used in the phantom experiments. In
addition, ultrasound activated phase change; the elevated
temperature of in vivo experiments is likely to facilitate the
phase conversion of smaller fluid filled C4F10 droplets in to
gaseous nanobubbles, enhancing the contrast signal.
Conclusions
We have demonstrated the first microfluidic preparation of
high concentrations of nanoparticles of C4F10 using a micro-
spray flow regime. Nanoparticles with diameters between 50
nm and 1 μm were produced at high concentration, of the
order 1011–1012 nanoparticles per mL, as counted and sized
by qNano, and of which ~1010 mL−1 were fluorocarbon drop-
lets. Nanoparticle populations were likely to be mix of liquid
and gaseous cores of C4F10 for diameters <1 μm. Ultrasound
measurements confirmed the presence of gas filled particles
that showed higher backscatter signal than water filled lipo-
somes of a similar size. Nanoparticles imaged in mice aorta
showed excellent contrast intensity when compared to samples
of mixed bubble sizes (micro- and nano-) and microbubbles
only, suggesting that at high frequencies used in pre-clinical
imaging, nanoparticles contribute highly to the contrast
intensity observed in US imaging. These nanoparticles have
the potential to provide higher resolution contrast imaging
when working at higher ultrasound frequencies. Further,
their ability to perfuse into tumours would provide better
resolution in diagnostic ultrasound and increase efficiency of
bubble based drug delivery systems. Future work will include
tailoring the microspray regime to preferentially produce
nanoparticles over micron sized bubbles by optimising flow
and gas pressures and bubble shell chemistry. Nanoparticles
will also be investigated for improved extra-cellular imaging
in tumours and drug delivery potential in in vitro and in vivo
models.
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